

**Table 4.10.3: Recommended use of 4vMenCV by age group for persons travelling to areas where epidemics of group A, C, W<sub>135</sub> or Y meningococcal disease occur or to mass gatherings**

Age at commencement of vaccine course	Recommended brand	Primary immunisation	Recommended interval between primary doses*	Timing of booster doses of 4vMenCV if required
2–6 months	Menveo	3 doses	8 weeks	At age 12–18 months, then 3 years later, then every 5 years thereafter
7–11 months	Menveo	2 doses	12 weeks	3 years after the primary doses, then every 5 years thereafter
12–23 months	<i>Either</i> Menveo	2 doses	12 weeks	3 years after the primary dose(s), then every 5 years thereafter
	<i>Or</i> Nimenrix	1 dose	Not applicable	
2–6 years	Menactra, Menveo or Nimenrix	1 dose	Not applicable	3 years after the primary dose, then every 5 years thereafter
≥7 years	Menactra, Menveo or Nimenrix <sup>†</sup>	1 dose	Not applicable	Every 5 years after the previous dose <sup>†</sup>

\* Refer to Table 2.1.7 *Minimum acceptable dose intervals for children <10 years of age* for advice on minimum intervals.

† 4vMenCV is preferred. However, 4vMenPV is a suitable alternative for travellers aged ≥7 years when the need for repeat doses is not anticipated (refer to 'Travellers' above).